FDA Clearance May Thwart Monograph Goal; Ganley Talks Turkey About ONP
This article was originally published in The Tan Sheet
Executive Summary
The Office of Nonprescription Products' goal of completing all OTC monographs by 2010 is viable only if FDA improves its document clearance process, according to ONP head Charles Ganley, MD
You may also be interested in...
Calls For Cough/Cold Collaboration As FDA Inches Toward Rulemaking
As FDA embarks on a lengthy rulemaking process to address pediatric OTC cough/cold products, the agency has strategies outside the regulatory framework available to effect any more immediate changes it deems necessary
Calls For Cough/Cold Collaboration As FDA Inches Toward Rulemaking
As FDA embarks on a lengthy rulemaking process to address pediatric OTC cough/cold products, the agency has strategies outside the regulatory framework available to effect any more immediate changes it deems necessary
NDAC Calls For Predefined Endpoints In Consumer Behavior Trials
Rx-to-OTC switch sponsors will be expected to work with FDA to establish predefined endpoints for each consumer behavior trial they plan, if the agency follows advice given by the Nonprescription Drugs Advisory Committee during a Sept. 25 meeting